Earnings Summary

Eli Lilly And Company’s revenue jumped 28.11% since last year same period to $8312.1Mn in the Q2 2023. On a quarterly growth basis, Eli Lilly And Company has generated 19.43% jump in its revenue since last 3-months.

Eli Lilly And Company’s net profit jumped 85.11% since last year same period to $1763.2Mn in the Q2 2023. On a quarterly growth basis, Eli Lilly And Company has generated 31.1% jump in its net profits since last 3-months.

Eli Lilly And Company’s net profit margin jumped 44.49% since last year same period to 21.21% in the Q2 2023. On a quarterly growth basis, Eli Lilly And Company has generated 9.78% jump in its net profit margins since last 3-months.

Eli Lilly And Company’s earning per share (EPS) estimates for the current quarter stand at 1.93 - a 0.52% jump from last quarter’s estimates.

Eli Lilly And Company’s earning per share (EPS) estimates for the current year stand at 1.93.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Eli Lilly And Company’s return on assets (ROA) stands at 0.1.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Eli Lilly And Company’s return on equity (ROE) stands at 0.66.

Eli Lilly And Company declared 1.13 dividend per share during the earnings announcement for Q1 2023.